Ground-breaking research funded by National Cancer Institute

Getty Images


September 28, 2022 —  Populations in U.S. counties defined as more vulnerable based on social factors including socioeconomic status and racial/ethnic minority status were significantly less likely to receive timely breast, cervical, and colorectal cancer screenings, according to research from UTHealth Houston

The Findings Were Published Today in JAMA Network Open

Disparities in screening rates were highly associated with a county’s social vulnerability index (SVI) – a tool that uses U.S. Census data to determine social vulnerability at a county or census tract level. The SVI is calculated using factors such as socioeconomic status, household composition, racial/ethnic minority status, housing type, transportation access, language barriers, and more among an area’s population. The index score helps public health officials and local planners better prepare for and respond to emergency events like hurricanes and disease outbreaks, which disproportionately affect areas with higher SVIs. 

The study was led by Cici Bauer, PhD, associate professor of biostatistics and data science, and Ryan Suk, PhD, assistant professor of management, policy and community health, both with UTHealth School of Public Health

“We found that counties with higher SVI scores had significantly lower screening rates for all three types of cancer,” Suk said. “These findings suggest that geographically targeted public health interventions could be further informed and improved by a composite measure reflecting the multidimensional measure of area-level social determinants of health.” 

Researchers discovered regional disparities in cancer screening rates at a county level across 3,141 U.S. counties, ranging from the lowest-performing county to the highest, including from 54.0% to 81.8% for breast cancer screening, from 69.9% to 89.7% for cervical cancer screening, and from 39.8% to 74.4% for colorectal cancer screening. 

“Even though cervical cancer screening rates are high overall, that doesn’t mean that is true everywhere,” Suk said. “Some populations have very low uptake, while in other areas, the cancer screening rate is higher than the national target rate. That’s why we have to focus on these differences by social determinants of health and not only overall average values.” 

The population-based, cross-sectional study used county-level information from the Centers for Disease Control and Prevention’s PLACES and SVI data sets from 2018 for the counties. Analyses were conducted from October 2021 to February 2022. 

Other Key Findings Included: 

The likelihood of having a cancer screening in the most vulnerable counties (or, the highest fifth) compared with the least vulnerable counties (the lowest fifth) was 14% lower for breast cancer, 20% lower for cervical cancer, and 28% lower for colorectal cancer. 

Some other area-level factors, such as rural/urban status and healthcare access in the county, were also associated with cancer screening rates. However, these factors did not further explain the geographic variation of the cancer screenings and did not change the association between social vulnerability and cancer screening rates. 

Generally, all three cancer screening rates were higher among counties on the east and west coasts and lower in the South. 

“Our study emphasizes the benefit of using geospatial analysis in population health for cancer research. It provides a powerful analytical tool to identify target areas for improving cancer prevention and reducing disparities,” Bauer said. “It also provides a way to understand how various social determinants of health may impact the cancer-related outcomes.” 

Overall, colorectal cancer screening rates were low throughout the U.S., Suk said, meaning public health experts should emphasize the importance of these screenings on a broad scale. 

For more information: https://www.uth.edu/ 


Related Content

News | Stroke

March 11, 2026 — Brainomix, a provider of AI-powered imaging tools for stroke and lung fibrosis, has announced the ...

Time March 11, 2026
arrow
News | Women's Health

March 4, 2026 — QT Imaging Holdings recently announced that Mary W. Yamashita, MD will serve as medical advisor to the ...

Time March 06, 2026
arrow
News | Radiation Oncology

March 4, 2026 — Lunit has announced that 21 studies featuring its AI solutions will be presented at the European ...

Time March 05, 2026
arrow
News | FDA

Feb. 26, 2026 — The U.S. Food and Drug Administration (FDA) has given 510(k) class II clearance of qXR-Detect, the ...

Time February 26, 2026
arrow
News | Women's Health

Feb.23, 2026 — The first clinical patient received a Clairity Breast cancer risk score, marking a historic milestone in ...

Time February 23, 2026
arrow
News | Breast Biopsy Systems

Feb. 18, 2026 — Mammotome, a Danaher company, has introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy ...

Time February 18, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
News | Radiopharmaceuticals and Tracers

Jan. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has launched a national program creating Authorized ...

Time January 30, 2026
arrow
Subscribe Now